BioSpace News Archive

Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today presented the first set of preclinical data for its lead oncology mRNA therapeutic, NTX-250, at the 37th annual Society for Immunotherapy of Cancer meeting.

ProKidney Corp., a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, announced that Dr. Tim Bertram, Chief Executive Officer, will participate in the following upcoming investor conferences.

The global biosurgery market size was USD 11.45 billion in 2020 and is expected to register a revenue CAGR of 5.4% during the forecast period.

Ascendis Pharma A/S (Nasdaq: ASND) today disclosed new data from the dose-escalation portion of transcendIT-101, the company’s Phase 1/2 open-label, multi-center trial of TransCon TLR7/8 Agonist in patients with advanced solid tumors.

DENTSPLY SIRONA Inc. announced its participation at upcoming conferences.

The National Kidney Foundation is pleased to announce that Dr. Kirk Campbell, the Irene and Dr. Arthur M. Fishberg Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Vice Chair of the Department of Medicine for Diversity, Equity, and Inclusion, has begun his two-year term as President Elect of NKF’s National Board of Directors.

Founded to address biological aging with gene therapy, BioViva Sciences is broadening its horizons.

Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted one employee a nonqualified stock option to purchase 30,000 shares of its common stock with an exercise price of $7.06 per share, which is equal to the closing price of Kezar’s common stock on November 7, 2022, the grant date of the award.

Fulcrum Therapeutics, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside of the Company’s 2019 Stock Incentive Plan.

The global Real Time Polymerase Chain Reaction (qPCR) market size was USD 4.64 Billion in 2021 and is expected to register a revenue CAGR of 7.8% during the forecast period.